Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans
NCT ID: NCT04218799
Last Updated: 2023-06-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
19 participants
INTERVENTIONAL
2014-08-12
2015-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Red Light Photobiomodulation and Topical Disinfectants
NCT05797818
Effect of Antibiotics on Urinary Microbiome
NCT04230746
The Effect of Skin Cleansers on the Skin Surface Microbiome
NCT03348917
Effect of an Antiseptic Solution on the Skin Microbiome
NCT05608382
Bacterial Decolonization Within Dyads
NCT06541145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intranasal Mupirocin and Topical Chlorhexidine
Intranasal Mupirocin and Topical Chlorhexidine
Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intranasal Mupirocin and Topical Chlorhexidine
Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Living in a participating nursing home for at least 80% of the past 3 months-
* Willing to provide anterior nares, posterior pharynx, skin and throat specimens over the study period.
* Willing to use intranasal mupirocin and topical chlorhexidine over a five day period.
* Provide signed and dated informed consent from subject or LAR.
Exclusion Criteria
* Use of mupirocin nasal ointment in past 3 months
* Use of topical chlorhexidine in past 3 months
* History of an allergic reaction to chlorhexidine or mupirocin
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary-Claire Roghmann
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary-Claire Roghmann, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loch Raven VA Community Living Center
Baltimore, Maryland, United States
Perry Point VA Community Living Center
Perry Point, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00058923
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.